» Articles » PMID: 35003591

The Mechanism of Raf Activation Through Dimerization

Overview
Journal Chem Sci
Specialty Chemistry
Date 2022 Jan 10
PMID 35003591
Authors
Affiliations
Soon will be listed here.
Abstract

Raf, a threonine/serine kinase in the Raf/MEK/ERK pathway, regulates cell proliferation. Raf's full activation requires dimerization. Aberrant activation through dimerization is an important therapeutic target. Despite its clinical importance, fundamental questions, such as how the side-to-side dimerization promotes the OFF-to-ON transition of Raf's kinase domain and how the fully activated ON-state kinase domain is stabilized in the dimer for Raf signaling, remain unanswered. Herein, we decipher an atomic-level mechanism of Raf activation through dimerization, clarifying this enigma. The mechanism reveals that the replacement of intramolecular π-π stacking by intermolecular π-π stacking at the dimer interface releases the structural constraint of the αC-helix, promoting the OFF-to-ON transition. During the transition, the inhibitory hydrophobic interactions were disrupted, making the phosphorylation sites in A-loop approach the HRD motif for -autophosphorylation. Once fully activated, the ON-state kinase domain can be stabilized by a newly identified functional N-terminal basic (NtB) motif in the dimer for Raf signaling. This work provides atomic level insight into critical steps in Raf activation and outlines a new venue for drug discovery against Raf dimerization.

Citing Articles

Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors.

Clayton J, Romany A, Matenoglou E, Gavathiotis E, Poulikakos P, Shen J Elife. 2025; 13.

PMID: 39945510 PMC: 11825127. DOI: 10.7554/eLife.95334.


Impact of protein and small molecule interactions on kinase conformations.

Kugler V, Schwaighofer S, Feichtner A, Enzler F, Fleischmann J, Strich S Elife. 2024; 13.

PMID: 39088265 PMC: 11293870. DOI: 10.7554/eLife.94755.


Signaling pathways in colorectal cancer implications for the target therapies.

Song Y, Chen M, Wei Y, Ma X, Shi H Mol Biomed. 2024; 5(1):21.

PMID: 38844562 PMC: 11156834. DOI: 10.1186/s43556-024-00178-y.


CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets.

Zhang W, Liu Y, Jang H, Nussinov R JACS Au. 2024; 4(5):1911-1927.

PMID: 38818077 PMC: 11134382. DOI: 10.1021/jacsau.4c00138.


Targeting RAF dimers in RAS mutant tumors: From biology to clinic.

Yin H, Tang Q, Xia H, Bi F Acta Pharm Sin B. 2024; 14(5):1895-1923.

PMID: 38799634 PMC: 11120325. DOI: 10.1016/j.apsb.2024.02.018.


References
1.
Huang T, Karsy M, Zhuge J, Zhong M, Liu D . B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6:30. PMC: 3646677. DOI: 10.1186/1756-8722-6-30. View

2.
Tran N, Wu X, Frost J . B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem. 2005; 280(16):16244-53. DOI: 10.1074/jbc.M501185200. View

3.
Morrison D, Cutler R . The complexity of Raf-1 regulation. Curr Opin Cell Biol. 1997; 9(2):174-9. DOI: 10.1016/s0955-0674(97)80060-9. View

4.
Holderfield M, Deuker M, McCormick F, McMahon M . Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014; 14(7):455-67. PMC: 4250230. DOI: 10.1038/nrc3760. View

5.
Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118(5):1739-49. PMC: 2289793. DOI: 10.1172/JCI33656. View